CATABASIS PHARMACEUTICALS IN's ticker is CATB and the CUSIP is 14875P107. A total of 24 filers reported holding CATABASIS PHARMACEUTICALS IN in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2018 | $363,000 | -85.6% | 453,740 | -74.6% | 0.00% | -100.0% |
Q2 2018 | $2,524,000 | +46.5% | 1,787,100 | +87.7% | 0.00% | -50.0% |
Q1 2018 | $1,723,000 | +146.8% | 952,200 | +103.2% | 0.00% | +100.0% |
Q4 2017 | $698,000 | +87.6% | 468,700 | +167.2% | 0.00% | – |
Q3 2017 | $372,000 | +131.1% | 175,400 | +53.2% | 0.00% | – |
Q2 2017 | $161,000 | +51.9% | 114,500 | +73.2% | 0.00% | – |
Q1 2017 | $106,000 | – | 66,100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SV Health Investors, LLC | 2,857,667 | $4,572,000 | 5.05% |
Clarus Ventures, LLC | 2,752,488 | $4,404,000 | 3.28% |
SPHERA FUNDS MANAGEMENT LTD. | 388,030 | $621,000 | 0.12% |
Rhenman & Partners Asset Management AB | 310,756 | $497,000 | 0.08% |
BOSTON FAMILY OFFICE LLC | 24,467 | $39,000 | 0.01% |
OPPENHEIMER & CO INC | 90,000 | $144,000 | 0.00% |
Alyeska Investment Group, L.P. | 221,281 | $354,000 | 0.00% |
A.R.T. Advisors, LLC | 46,747 | $74,000 | 0.00% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 101,347 | $162,000 | 0.00% |
Acrospire Investment Management LLC | 680 | $1,000 | 0.00% |